中国医学创新Issue(13)：60-62,3.DOI:10.3969/j.issn.1674-4985.2014.13.021
熊去氧胆酸治疗婴儿胆汁淤积型巨细胞病毒性肝炎的临床评价
Clinical Evaluation to Baby Cholestasis Type CMV Hepatitis with Ursodeoxycholic Acid Treatment
葛兴净 1吴仕梅 1于翠云 1于绍桂1
作者信息
- 1. 山东省日照市莒县人民医院 山东 莒县 276500
- 折叠
摘要
Abstract
Objective: To study the effect and safety of UDCA (Ursodeoxycholic acid) capsule treatment for infantile CMV hepatitis with cholestasis.Method: 40 pediatric patients were divided into 2 groups: 20 cases in UDCA group, 20 cases in control group. Both of the 2 groups were given routine therapy including antiviral therapy, improvement of liver functions and comprehensive treatment. UDCA was used in treatment of patients in trial group in addition to the routine therapy. Their clinical features and the levels of serum ALP, GGT, TBIL, et al, were evaluated and compared. The therapeutic effect were assessed and compared after taking drugs for 2 weeks.Result: Levels of ALP, GGT, TBIL, DBIL, TBA, AKP, GGT in each of the 2 groups decreased significantly(P<0.05). The levels of TBIL and DBIL significantly decreased in the UDCA group (P<0.05).Conclusion: UDCA capsule can promote bile acid excretion, accelerate the jaundice subsided, improve liver function biochemical parameters of infantile CMV hepatitis with cholestasis. It is safe and effective without obvious adverse reactions. It is worth promoting.关键词
熊去氧胆酸/胆汁淤积/巨细胞病毒性肝炎Key words
Ursodeoxycholic acid/Cholestasis/CMV hepatitis引用本文复制引用
葛兴净,吴仕梅,于翠云,于绍桂..熊去氧胆酸治疗婴儿胆汁淤积型巨细胞病毒性肝炎的临床评价[J].中国医学创新,2014,(13):60-62,3.
